Drug intelligence / Profile preview

99mtc-rwy

Development stage: Phase 1
Lead developer: Peking University
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

99mTc-RWY is an experimental radiopharmaceutical composed of the RWY peptide labeled with the radionuclide technetium-99m. The RWY peptide targets integrin α6, a protein overexpressed in various tumors. By binding to integrin α6, 99mTc-RWY enables targeted imaging of tumors using single photon emission computed tomography (SPECT). Preclinical studies and early clinical imaging in breast cancer patients have demonstrated its ability to clearly visualize tumor lesions. This agent is under investigation primarily for cancer imaging applications, including colorectal and breast cancers[8].

Other names: technetium-99m rwytechnetium99m rwytechnetium 99m rwy99mTc-RWY

Targets

ITGA6 (Integrin alpha-6)

Beyond the preview

Go deeper on 99mtc-rwy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mtc-rwy.

Explore the full profile